SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is driving intense retail and institutional debate as the stock experiences extreme volatility and price appreciation following its debut. Investors remain deeply divided, with bulls pointing to the company's dominance in space infrastructure and AI potential, while bears warn of unsustainable valuations, negative cash flows, and the risks associated with an upcoming lock-up expiration.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. is trending as investors highlight its role as a proxy for the rapidly growing HYPE crypto ecosystem, with the community closely tracking potential gamma squeeze mechanics and upcoming Russell index inclusion. Sentiment is largely bullish, driven by the firm's treasury buyback model and institutional capital inflows, though some participants remain cautious due to the stock's elevated volatility.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending following a significant leadership transition, with Takis Georgakopoulos taking over as CEO amid a period of severe share price decline and investor frustration. The market is weighing the abrupt exit of the previous CEO and concerns over company-specific growth against the potential for an institutional valuation reset and long-term value opportunities.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is seeing intense momentum as storage providers benefit from an industry-wide cycle of increasing demand for high-capacity data storage and enterprise infrastructure spending. The community is actively discussing the stock's role in the memory and storage boom alongside peers like Micron and Seagate, with many traders debating the sustainability of current price levels against the ongoing supply discipline and record-setting momentum.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is trending amid intense market discussion regarding its massive acquisition of Roku, which has sparked significant debate among retail investors over long-term strategic value versus immediate dilution concerns. While some community members view the move as an aggressive push into connected TV and ad-tech, others express skepticism about integration risks and the potential impact on the company's valuation.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo is trending following a new distribution agreement with NBCUniversal that restores key channels to the platform, sparking debate between bulls who view the content deal as a catalyst for subscriber growth and bears skeptical of management's track record and stock performance. Community discourse remains highly polarized, with some investors focused on potential long-term value and Disney's influence, while vocal detractors continue to criticize leadership and the stock's multi-year downward trend.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is attracting intense attention after announcing a secondary offering at a significant discount, sparking a sharp sell-off despite ongoing enthusiasm for the company's CRISPR-based gene editing platform. The community is deeply divided, with some investors panic-selling over dilution concerns while others view the dip as a strategic long-term buying opportunity given the firm's de-risked clinical pipeline and high short interest.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is currently drawing significant community attention as it navigates aggressive expansion into physical AI, humanoid robotics, and autonomous driving technology, while investors remain split between the stock's long-term technological potential and frustration over its persistent underperformance compared to other EV sector participants. While proponents point to strategic collaborations and robust product innovation as foundational strengths, the broader conversation is heavily dominated by skepticism regarding valuation, geopolitical headwinds, and the stock's ongoing volatility on the NYSE.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh the stock's long-term growth potential against significant arbitration overhangs and volatile geopolitical headlines regarding Middle East energy transit. While the community remains divided over the impact of ongoing litigation and insider share activity, bullish sentiment is supported by a strong $134 billion backlog and rising LNG demand for data centers.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

The UVXY is experiencing significant volatility-driven trading as market participants weigh conflicting signals between bullish index momentum and intensifying geopolitical tensions in the Strait of Hormuz. Community discussion is heavily divided between traders attempting to time sudden volatility spikes and skeptics who maintain that the ETF's structural decay makes it an unreliable long-term hedge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (Grace or the Company) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace...

GRCE Stock On Track For Worst Week In 5.5 Years —  What’s Driving The Selloff?

Equity

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.


GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. 


GRCE Stock In Spotlight Ahead Of FDA Verdict On Brain Bleed Drug This Week 

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8%

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.23	--	--	N/A
Q3 '25	-$0.28	-$0.14	50.00%	BEAT
Q2 '25	-$0.25	-$0.06	76.11%	BEAT
Q1 '25	-$0.22	-$0.21	4.55%	BEAT
Q4 '24	-$0.28	$0.11	139.64%	BEAT

GRCEGrace Therapeutics Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest GRCE News